全球靜脈注射免疫球蛋白市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計靜脈注射免疫球蛋白市場將從 2025 年的 129 億美元成長到 2034 年的 249.2 億美元，2026 年至 2034 年的複合年成長率為 7.59%。

由於治療免疫力缺乏和自體免疫疾病的需求不斷成長，全球靜脈注射免疫球蛋白市場經歷了顯著成長。靜脈注射免疫球蛋白是一種血液衍生治療方法，用於增強免疫系統和治療多種疾病。其對原發性免疫力缺乏缺陷症和神經系統疾病等疾病的療效促進了其廣泛應用。

關鍵促進因素包括免疫相關疾病盛行率的上升以及人們對先進治療方法的認知不斷提高。醫療專業人員越來越依賴靜脈注射免疫球蛋白療法來治療複雜疾病並改善患者預後。此外，血漿採集和純化技術的進步正在擴大產能並提高治療的可及性。

隨著免疫相關疾病研究的不斷深入，靜脈注射免疫球蛋白市場預計將持續成長。醫療基礎設施的擴張和診斷能力的提升可能會增加治療需求。血漿衍生療法的持續創新和臨床應用的不斷拓展，有望支撐該市場的長期發展。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球靜脈注射免疫球蛋白市場：依應用領域分類

• 市場分析、洞察與預測
• 免疫不全症
• CIDP
• 低丙種球蛋白血症
• 先天性愛滋病
• 慢性淋巴性白血病
• 重症肌無力
• 多灶性運動神經病變
• ITP
• 川崎病
• Guillain-Barré二氏症候群
• 其他

第5章：全球靜脈注射免疫球蛋白市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 專科藥房
• 其他

第6章 全球靜脈注射免疫球蛋白市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Biotest AG
  • Baxter
  • Octapharma AG
  • LFB
  • Grifols SA
  • CSL
  • China Biologics Products Inc
  • Kedrion
  • BDI Pharma Inc

The Intravenous Immunoglobulin Market size is expected to reach USD 24.92 Billion in 2034 from USD 12.90 Billion (2025) growing at a CAGR of 7.59% during 2026-2034.

The global intravenous immunoglobulin market has experienced substantial growth due to increasing demand for therapies that treat immune deficiencies and autoimmune diseases. Intravenous immunoglobulin is a blood-derived therapy used to strengthen the immune system and manage various medical conditions. Its effectiveness in treating disorders such as primary immunodeficiency and neurological diseases has contributed to widespread adoption.

Key drivers include rising prevalence of immune-related disorders and growing awareness of advanced treatment options. Healthcare providers increasingly rely on intravenous immunoglobulin therapy to manage complex conditions and improve patient outcomes. Additionally, advancements in plasma collection and purification technologies have helped expand production capacity and improve treatment availability.

Looking ahead, the intravenous immunoglobulin market is expected to grow as research into immune-related diseases continues to advance. Expanding healthcare infrastructure and improved diagnostic capabilities may increase treatment demand. Ongoing innovation in plasma-derived therapies and expanding clinical applications are likely to support the long-term development of this market.

MARKET SEGMENTATION

By Application

• Immunodeficiency diseases
• CIDP
• Hypogammaglobulinemia
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal motor neuropathy
• ITP
• Kawasaki disease
• Guillain-Barre syndrome
• Others

By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Other

COMPANIES PROFILED

• Biotest AG, Baxter, Octapharma AG, LFB, Grifols SA, CSL, China Biologics Products Inc, Kedrion, BDI Pharma Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Immunodeficiency diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. CIDP Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Hypogammaglobulinemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Congenital AIDS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Chronic Lymphocytic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Myasthenia Gravis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Multifocal motor neuropathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. ITP Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.10. Kawasaki disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.11. Guillain-Barre syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.12. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Specialty Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Application
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Application
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Application
  • 6.4.2 By Distribution Channel
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Application
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Application
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL INTRAVENOUS IMMUNOGLOBULIN INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Biotest AG
  • 8.2.2 Baxter
  • 8.2.3 Octapharma AG
  • 8.2.4 LFB
  • 8.2.5 Grifols SA
  • 8.2.6 CSL
  • 8.2.7 China Biologics Products Inc
  • 8.2.8 Kedrion
  • 8.2.9 BDI Pharma Inc